Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02970318 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT02970318 · ClinicalTrials.gov record · last posted 2026-07-24

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

StatusActive, Not Recruiting
PhasePhase 3
Started2017-02-02
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).

Amendment record 28 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 28 times since 2016-11-18; most recent amendment 2026-07-22. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2019-03-14
Status change Recruiting→Active, Not Recruitingv4
Trial Details
NCT Number NCT02970318
Lead Sponsor Acerta Pharma BV
Conditions Chronic Lymphocytic Leukemia
Enrollment 310 participants
Start Date 2017-02-02
Primary Completion 2021-09-03 (estimated)
Study Completion 2027-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-24